Cell Line News and Research

RSS

Sunshine Biopharma completes Adva-27a cytotoxicity study on multidrug-resistant lung cancer

Sunshine Biopharma Inc., a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has completed a cytotoxicity study of its lead compound, Adva-27a, in H69AR, a Multidrug Resistant Small Cell Lung Cancer cell line. Cytotoxicity studies measure the ability of a drug to destroy cancer cells in vitro.

27 Jun 2012

Faulty conclusions due to contamination, misidentification and redundancy in widely available cell lines

Modern cancer therapies start in cells - researchers compare cancer samples to healthy cells to discover how cancer is genetically different, and use cell lines to test promising new drugs. However, a University of Colorado Cancer Center study published this week in the journal Gynecologic Oncology shows that due to a high rate of contamination, misidentification and redundancy in widely available cell lines, researchers may be drawing faulty conclusions.

22 Jun 2012

New U-M hESC lines now available for federally-funded research

Six new human embryonic stem cell lines derived at the University of Michigan have just been placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research.

15 Jun 2012

ABL to perform process development and cGMP manufacturing of recombinant scuPA

Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung.

14 Jun 2012

CDI introduces MyCell Services

Cellular Dynamics International, Inc. (CDI), the world's largest commercial producer of human induced pluripotent stem (iPS) cell lines and tissue cells, today announced the launch of its MyCell Services.

7 Jun 2012

InVitria receives new SBIR grant from NIAID

Ventria Bioscience today announced that its non-therapeutic products division InVitria has been awarded a new Small Business Innovation Research Program (SBIR) grant from the National Institutes of Health, National Institute of Allergy and Infectious Diseases.

6 Jun 2012

Ancient berry could protect against diabetic retinopathy

The ancient Tibetan goji berry could help fight blindness caused by long-term diabetes according to studies conducted by University of Sydney researchers.

5 Jun 2012

JMC publishes results from Rexahn’s RX-3117 preclinical cancer study

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company developing and commercializing potential best in class oncology and CNS therapeutics, today announced the publication of a research article in Journal of Medicinal Chemistry on the anti-tumor activity of its RX-3117 compound.

1 Jun 2012

New medicine can start and hasten healing of diabetic and other chronic sores

A unique new medicine that can start and hasten healing of diabetic and other chronic sores is being developed at Umeå University in Sweden. After several years of successful experimental research, it is now ready for clinical testing.

28 May 2012

Breast cancer cell surface protein blows cover of potent tumor-generating cells

Breast cancer stem cells wear a cell surface protein that is part nametag and part bull's eye, identifying them as potent tumor-generating cells and flagging their vulnerability to a drug, researchers at The University of Texas MD Anderson Cancer Center report online in Journal of Clinical Investigation.

17 May 2012

Researchers use clever screening methods to speed vaccine production

Infectious diseases-both old and new-continue to exact a devastating toll, causing some 13 million fatalities per year around the world. Vaccines remain the best line of defense against deadly pathogens and now Kathryn Sykes and Stephen Johnston, researchers at Arizona State University's Biodesign Institute, along with co-author Michael McGuire from the University of Texas Southwestern Medical Center are using clever functional screening methods to attempt to speed new vaccines into production that are both safer and more potent.

10 May 2012

UMD researchers design molecular container that can increase solubility of drugs

A cross-disciplinary team of researchers at the University of Maryland has designed a molecular container that can hold drug molecules and increase their solubility, in one case up to nearly 3000 times. Their discovery opens the possibility of rehabilitating drug candidates that were insufficiently soluble. It also offers an opportunity to improve successful drugs that could be made even better with better solubility.

9 May 2012

BioDiem announces new vaccine research collaboration with French-based VIVALIS

Australian vaccine development company BioDiem Ltd (ASX: BDM) today announced that it has begun a research collaboration with France-based VIVALIS (Euronext code: VLS), a biopharmaceutical company with expertise in vaccine production technologies.

9 May 2012

Human stem cells effective in treating muscular dystrophy

Researchers from the University of Minnesota's Lillehei Heart Institute have effectively treated muscular dystrophy in mice using human stem cells derived from a new process that - for the first time - makes the production of human muscle cells from stem cells efficient and effective.

5 May 2012

PDE4 enzyme regulates division of tumour cells and blood vessel growth in cancer tissue

Lung cancer is the leading cause of cancer death throughout the world. Standard treatment methods do not usually result in long-term recovery. In addition to the proliferation of the tumour cells, the growth of blood vessels controls tumors development. The blood vessel growth is controlled by several signalling molecules. Scientists from the Max Planck Institute for Heart and Lung Research in Bad Nauheim and Justus Liebig University Giessen have discovered a molecule that plays a key role in this process. They succeeded in reducing tumour growth in their experiments by blocking the phosphodiesterase PDE4.

5 May 2012

Human iPS cells accrue genetic changes at about the same rate as replicating cells

A team of researchers from Johns Hopkins University and the National Human Genome Research Institute has evaluated the whole genomic sequence of stem cells derived from human bone marrow cells—so-called induced pluripotent stem (iPS) cells—and found that relatively few genetic changes occur during stem cell conversion by an improved method.

30 Apr 2012

U-M’s second human embryonic stem cell line now available for federally-funded research

The University of Michigan's second human embryonic stem cell line has just been placed on the U.S. National Institutes of Health's registry, making the cells available for federally-funded research. It is the second of the stem cell lines derived at U-M to be placed on the registry.

26 Apr 2012

Leica receives FDA Pre-Market Approval for new HER2 IHC test

Leica Biosystems, a division of Leica Microsystems, announced that it has received Pre-Market Approval from the U.S. Food and Drug Administration for the Leica Bond Oracle HER2 IHC System with the Leica BOND-MAX, establishing their commitment to developing quality companion diagnostic products.

26 Apr 2012

Method to manufacture cartilage from human embryonic stem cells

BioTime, Inc. and its wholly owned subsidiary OrthoCyte Corporation reported today a means of manufacturing cartilage from human embryonic stem cells that is suited for industrial scale-up of a product for the treatment of osteoarthritis.

23 Apr 2012

Chinese scientists make significant breakthrough in animal cloning

Chinese scientists from BGI, the world's largest genomics organization, together with the Institute of Genetics and Developmental Biology, Chinese Academy of Sciences (CAS), and Shihezi University, Xinjiang province, made a significant breakthrough in animal cloning.

20 Apr 2012